• "The minimum biopsy size was 1.7 cm and the number of portal areas 10. Liver biopsies were scored the severity of fibrosis according to Ishak for CHC patients [34] and NAFLD clinical research network activity score for NAFLD patients [35]. Severe fibrosis was defined as Ishak fibrosis score F4–F6 for CHC patients or NAFLD fibrosis stage F3–F4 for NAFLD patients. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Increased levels of adiponectin, a major adipokine with insulin sensitizing properties showing a strong sexual dimorphism, have been reported in individuals with chronic HCV infection (CHC), but data are limited by small samples and lack of control for the genetic background and hepatic fibrosis. The aim of this study was to compare adiponectin levels between CHC patients and accurately matched controls. We considered 184 CHC patients, matched (1:1) for age, gender, body mass index, and Adiponectin genotype (ADIPOQ) with healthy individuals. To control for the severity of liver disease, a second control group consisting of 95 patients with histological nonalcoholic fatty liver disease (NAFLD) further matched (1:1) for severe fibrosis was exploited. ADIPOQ genotype was evaluated by Taqman assays, serum adiponectin measured by ELISA. Serum adiponectin was higher in CHC patients than in healthy individuals (9.0±5.0μg/ml vs. 7.3±4.0μg/ml; p=0.001; adjusted estimate +1.8, 1.7-2.9; p=0.001), and than in NAFLD patients (8.3±4.5μg/ml vs. 6.0±4.2μg/ml; p<0.001; adjusted estimate +0.8, 0.2-1.4, p=0.006). After stratification for sex, serum adiponectin was higher in males with CHC than in healthy individuals and NAFLD patients (p<0.005 for both), whereas the difference was not significant in females. CHC is associated with increased serum adiponectin independently of age, body mass, diabetes, ADIPOQ genotype, and of severe liver fibrosis, particularly in men. Copyright © 2015 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
    European Journal of Internal Medicine 08/2015; DOI:10.1016/j.ejim.2015.08.001 · 2.89 Impact Factor
    • "Study group, anti-HCV (+) HCV-RNA (−) individuals; SVR, sustained virological responders; CHC, patients with chronic HCV infection; ALT, alanine aminotransferase; NA, not applicable. a Histological activity index and fibrosis scores of liver biopsies were determined as described by Ishak et al [18]. Fig. 2. (A) HCV-and (B) influenza-specific lymphocyte response. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) status cannot be reliably predicted in anti-HCV positive/HCV-RNA negative individuals who may either have recovered spontaneously or have a false-positive test due to antibody cross-reaction. Investigating T lymphocyte responses in individuals with different HCV status may help understand the cellular immune mechanisms underlying spontaneous recovery, treatment response, and chronicity. We aimed to determine whether anti-HCV positive, HCV-RNA negative individuals are truly spontaneous recoverers from acute HCV infection. We used enzyme-linked immunosorbent spot (ELISPOT) assay to compare HCV-specific lymphocyte response among anti-HCV positive/HCV-RNA negative individuals, patients with sustained virological response to interferon-γ/ribavirin treatment, and patients with chronic HCV infection. We found that 83% of anti-HCV positive/HCV-RNA negative individuals without a past medical history of acute icteric hepatitis had an HCV-specific T lymphocyte response in peripheral blood. Lymphocyte responses in these individuals were similar in magnitude to treatment responders unlike patients with chronic HCV whose virus-directed immunity was significantly suppressed. Detection of HCV-specific T lymphocyte responses using ELISPOT is a feasible method to ascertain past asymptomatic acute HCV infection. Copyright © 2015 Elsevier B.V. All rights reserved.
    Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 04/2015; 67. DOI:10.1016/j.jcv.2015.04.014 · 3.02 Impact Factor
  • Source
    • "Specimens were reviewed by the same pathologist (GB). Liver fibrosis was graded according to Ishak et al. [23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Hyperferritinemia is frequent in chronic liver diseases of any cause, but the extent to which ferritin truly reflects iron stores is variable. In these patients, both liver iron and fat are found in variable amount and association. Liver biopsy is often required to quantify liver fat and iron, but sampling variability and invasiveness limit its use. We aimed to assess single breath-hold multiecho magnetic resonance imaging (MRI) for the simultaneous lipid and iron quantification in patients with hyperferritinemia. Material and methods: We compared MRI results for both iron and fat with their respective gold standards - liver iron concentration and computer-assisted image analysis for steatosis on biopsy. We prospectively studied 67 patients with hyperferritinemia and other 10 consecutive patients were used for validation. We estimated two linear calibration equations for the prediction of iron and fat based on MRI. The agreement between MRI and biopsy was evaluated. Results: MRI showed good performances in both the training and validation samples. MRI information was almost completely in line with that obtained from liver biopsy. Conclusion: Single breath-hold multiecho MRI is an accurate method to obtain a valuable measure of both liver iron and steatosis in patients with hyperferritinemia.
    Scandinavian Journal of Gastroenterology 01/2015; 50(4):1-10. DOI:10.3109/00365521.2014.940380 · 2.36 Impact Factor
Show more